Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 9.
doi: 10.1002/bab.70046. Online ahead of print.

Ribonuclease-Based Immunotoxins as Anticancer Agents

Arezoo Mesri  1 , Negar Asadi  2 , Hadi Maleki-Kakelar  3 , Amir Maleksabet  4 , Ramin Saadatian Kharajo  5 , Mortaza Taheri-Anganeh  2   6 , Saeid Latifi-Navid  1
Affiliations
Review

Ribonuclease-Based Immunotoxins as Anticancer Agents

Arezoo Mesri et al. Biotechnol Appl Biochem. .

Abstract

Ribonucleases (RNases) represent a distinct category of nucleases that facilitate RNA degradation into smaller components. These enzymes are particularly adept at dismantling RNA strands and other materials. A promising strategy for the targeted treatment of cancer cells involves the administration of antibody-based toxic agents designed to eliminate tumor cells specifically. These poisonous agents may include synthetic small-molecule drugs or cytotoxic proteins known as immunotoxins (ITs). ITs are defined by their dual structure, comprising a receptor-targeting element and a cytotoxic component, which may be derived from RNase sourced from plants, bacteria, fungi, or humans. When RNases are used as IT, they can trigger cell cycle arrest or interfere with vital cellular pathways, ultimately leading to apoptosis or the specific destruction of cancer cells. Consequently, this review highlights the application of various RNases in cancer treatment, underscoring their cytotoxic properties, which are crucial for advancing research on health and therapeutic interventions.

Keywords: cancer; immunotoxin; ribonuclease.

PubMed Disclaimer

References

    1. F. Bray, M. Laversanne, E. Weiderpass, and I. Soerjomataram, “The Ever‐Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide,” Cancer 127, no. 16 (2021): 3029–3030.
    1. B. Z. Sibuh, R. Gahtori, N. Al‐Dayan, et al., “Emerging Trends in Immunotoxin Targeting Cancer Stem Cells,” Toxicology In Vitro 83 (2022): 105417.
    1. J. Sun, J. Luo, F. Jiang, et al., “Exploring the Cross‐Cancer Effect of Circulating Proteins and Discovering Potential Intervention Targets for 13 Site‐Specific Cancers,” JNCI: Journal of the National Cancer Institute 116, no. 4 (2024): 565–573.
    1. M. Nassiri, V. Gopalan, and M. Vakili‐Azghandi, “Modifications of Ribonucleases in Order to Enhance Cytotoxicity in Anticancer Therapy,” Current Cancer Drug Targets 22, no. 5 (2022): 373–387.
    1. A. Forouharmehr, M. Nassiri, S. Ghovvati Roudsari, and A. Javadmanesh, “Production and Introduction of a Novel Immunotoxin Based on Engineered RNase A for Inducing Death to Her1‐Positive Cell Lines,” Journal of Cellular Physiology 235, no. 5 (2020): 4679–4687.

LinkOut - more resources